Kohjin Bio (177A) Stock Overview
Manufactures and sells of animal blood, sera, tissue culture media, media for microbiology testing, in vitro diagnostic agents, and cosmetics. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
+ 1 more risk
177A Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Kohjin Bio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥957.00 |
| 52 Week High | JP¥2,020.00 |
| 52 Week Low | JP¥955.00 |
| Beta | -0.035 |
| 1 Month Change | -11.22% |
| 3 Month Change | -19.92% |
| 1 Year Change | -43.71% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -59.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| 177A | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -2.8% | -0.8% | -2.3% |
| 1Y | -43.7% | -30.4% | 40.4% |
Return vs Industry: 177A underperformed the JP Biotechs industry which returned -30.4% over the past year.
Return vs Market: 177A underperformed the JP Market which returned 40.4% over the past year.
Price Volatility
| 177A volatility | |
|---|---|
| 177A Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in JP Market | 9.3% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 177A's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 177A's weekly volatility has increased from 7% to 13% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 167 | Takahito Nakamura | www.kohjin-bio.jp |
Kohjin Bio Co., Ltd. manufactures and sells of animal blood, sera, tissue culture media, media for microbiology testing, in vitro diagnostic agents, and cosmetics. The company offers tissue culture mediums for human cell culture, including human lymphocyte culture, hepatoblastoma-derived cell lines, adipose- derived stem cells, neural stem cells, fibroblast, vascular endothelial cells, and epidermal keratinocyte human cell cultures. It also provides industrial cell cultures for CHO, hybridomas, and insect cells; exosome production; cryopreservation solutions; cell dissociation agents; adoptCell-NK kits, and bag and other materials.
Kohjin Bio Co., Ltd. Fundamentals Summary
| 177A fundamental statistics | |
|---|---|
| Market cap | JP¥4.89b |
| Earnings (TTM) | JP¥251.00m |
| Revenue (TTM) | JP¥4.94b |
Is 177A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 177A income statement (TTM) | |
|---|---|
| Revenue | JP¥4.94b |
| Cost of Revenue | JP¥3.08b |
| Gross Profit | JP¥1.86b |
| Other Expenses | JP¥1.61b |
| Earnings | JP¥251.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 49.10 |
| Gross Margin | 37.60% |
| Net Profit Margin | 5.08% |
| Debt/Equity Ratio | 31.5% |
How did 177A perform over the long term?
See historical performance and comparisonDividends
Does 177A pay a reliable dividends?
See 177A dividend history and benchmarks| Kohjin Bio dividend dates | |
|---|---|
| Ex Dividend Date | Mar 30 2026 |
| Dividend Pay Date | Jun 29 2026 |
| Days until Ex dividend | 90 days |
| Days until Dividend pay date | 1 day |
Does 177A pay a reliable dividends?
See 177A dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/27 23:54 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kohjin Bio Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kyoichiro Shigemura | Nomura Securities Co. Ltd. |